04:49:48 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande


Inhalation Sciences Sweden, ISAB, är ett forskningsbolag. Idag innehas störst fokus mot framställning och utvecklande av laboratorieinstrument. Instrumenten används för att mäta partiklar i inandningsluften och hur luftens sammansättning påverkar lungorna. Bolaget säljer produkter under varierade varumärken, främst på den europeiska marknaden. Inhalation Sciences Sweden grundades 2004 och har sitt huvudkontor i Huddinge.


2022-11-22 Kvartalsrapport 2022-Q3
2022-08-29 Kvartalsrapport 2022-Q2
2022-06-08 Ordinarie utdelning ISAB 0.00 SEK
2022-05-23 Kvartalsrapport 2022-Q1
2022-05-06 Årsstämma 2022
2022-02-28 Bokslutskommuniké 2021
2021-11-24 Kvartalsrapport 2021-Q3
2021-08-26 Kvartalsrapport 2021-Q2
2021-06-22 Extra Bolagsstämma 2021
2021-06-09 Ordinarie utdelning ISAB 0.00 SEK
2021-06-08 Årsstämma 2021
2021-05-19 Kvartalsrapport 2021-Q1
2021-02-25 Bokslutskommuniké 2020
2020-11-26 Kvartalsrapport 2020-Q3
2020-08-26 Kvartalsrapport 2020-Q2
2020-06-12 Extra Bolagsstämma 2020
2020-05-13 Ordinarie utdelning ISAB 0.00 SEK
2020-05-12 Årsstämma 2020
2020-05-07 Kvartalsrapport 2020-Q1
2020-02-20 Bokslutskommuniké 2019
2019-11-14 Kvartalsrapport 2019-Q3
2019-08-22 Kvartalsrapport 2019-Q2
2019-05-22 Årsstämma 2019
2019-05-16 Kvartalsrapport 2019-Q1
2019-05-10 Ordinarie utdelning ISAB 0.00 SEK
2019-02-21 Bokslutskommuniké 2018
2018-12-13 Extra Bolagsstämma 2018
2018-11-15 Kvartalsrapport 2018-Q3
2018-08-22 Kvartalsrapport 2018-Q2
2018-05-24 Ordinarie utdelning ISAB 0.00 SEK
2018-05-23 Årsstämma 2018
2018-05-16 Kvartalsrapport 2018-Q1
2018-02-22 Bokslutskommuniké 2017
2017-11-17 Kvartalsrapport 2017-Q3
2017-08-28 Kvartalsrapport 2017-Q2
2021-11-09 08:10:21

(Stockholm, 9 November 2021) The new order, worth 355 000 SEK, is with long-term client Chiesi (Chiesi Farmaceutici S.p.A), a leading company within asthma and COPD. Chiesi has ordered ISAB's new in vivo mouse exposure module. Mice are the preferred test subject for the development of biologic drugs, making ISAB's new high-precision, one-animal-at-a-time module extremely relevant for the growing number of companies currently developing inhaled biologics, rather than traditional small molecule therapies.

ISAB's new mouse exposure module is a new entry into PreciseInhale's extensive suite of exposure modules. The new module offers great flexibility as well as precision to drug developers. It precisely generates controlled aerosol to single animals through either Nose-Only or Intratracheal exposures, generating high-precision data and significantly reducing the need for large numbers of test animals.

Mice are the preferred test subject for the development of biologic drugs, sharing a high degree of homology with humans and enabling researchers to work with an extensive range of disease models. PreciseInhale's new mouse module makes the system even more relevant to the growing number of advanced companies working on inhaled biologics, such as proteins, rather than traditional small molecules.

ISAB CEO Manoush Masarrat: "We're delighted with this new sale to such an innovative and esteemed customer. It really validates our scientific `aerosol switchboard' model - where we offer inhaled drug developers a comprehensive choice of exposure modules - and it brings all the advantages of precision dosing to the highly valuable area of mouse exposures. We're proud and pleased to continue our long, much-valued relationship with Chiesi."